Zymeworks will be attending and presenting at the Respiratory Innovation Summit, taking place May 15–16, 2026, in Orlando, FL.
Hosted by the American Thoracic Society, the 2026 Respiratory Innovation Summit brings together innovators, investors, clinicians, and advocacy groups at the forefront of developing powerful new treatments for deadly and debilitating diseases of the lungs and airways.
On May 15 and 16, Zymeworks will present “ZW1528: IL-4Rα x IL-33 Bispecific Antibody for Treatment of COPD” (Poster #117). Members of our team will be onsite and available to discuss our atopic and inflammatory immunology disease (AIID) programs — we look forward to connecting with attendees. The presentation will be available on Zymeworks’ website at zymeworks.com/publications/ at the time of the poster session.
About ZW1528
Zymeworks’ first program in AIID, is a novel IL-4R⍺ x IL-33 bispecific molecule designed to address respiratory inflammation such as mixed-type chronic obstructive pulmonary disease (COPD) by inhibiting multiple pathways. By blocking three cytokines (IL-4, IL-13, and IL-33) in a single biologic, ZW1528 offers a unique approach to inhibit clinically validated pathways. The bispecific antibody is designed to provide complete, prolonged IL-4R⍺ blockade with simultaneous blockade of IL-33. Based on non-clinical in vitro studies, the bispecific can independently suppress IL-4, IL-13, and IL-33 driven cell signaling equivalent to that achieved with anti-IL-4R⍺ monoclonal antibody (mAb) or anti-IL-33 clinical benchmarks mAbs. Furthermore, in preclinical studies, ZW1528-mediated blockade of cytokine-driven activation of human epithelial cells was superior to that achieved with mAbs targeting either IL-4R⍺ or IL-33, indicating potential benefits of dual blockade. Additionally, preclinical studies with human peripheral blood mononuclear cells demonstrate ZW1528 provides blockade of IL-33 mediated effects beyond that achievable with an anti-IL33 benchmark mAb. With native Immunoglobulin G-like geometry, ZW1528 demonstrates the potential for high manufacturability and incorporates half-life extending Fc modifications.
Partnering at Zymeworks
Partnerships are central to Zymeworks’ corporate strategy, enabling the company to expand and accelerate its efforts to bring novel multifunctional therapeutics to the broadest group of patients in the most efficient manner possible.
Learn more about our active partnerships and partnering focus here.
